Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
CAS Article PubMed PubMed Central Google Scholar
Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6(3):231–43. https://doi.org/10.1038/nri1783.
CAS Article PubMed Google Scholar
Antia A, Ahmed H, Handel A, Carlson NE, Amanna IJ, Antia R, et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 2018;16(8): e2006601. https://doi.org/10.1371/journal.pbio.2006601.
CAS Article PubMed PubMed Central Google Scholar
Smatti MK, Al Thani AA, Yassine HM. Viral-induced enhanced disease illness. Front Microbiol. 2018;9:2991. https://doi.org/10.3389/fmicb.2018.02991.
Article PubMed PubMed Central Google Scholar
Eidem S, Tete SM, Jul-Larsen Å, Hoschler K, Montomoli E, Brokstad KA, et al. Persistence and avidity maturation of antibodies to A(H1N1) pdm09 in healthcare workers following repeated annual vaccinations. Vaccine. 2015;33(33):4146–54. https://doi.org/10.1016/j.vaccine.2015.05.081.
Lee YC, Kelly DF, Yu LM, Slack MP, Booy R, Heath PT, et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008;46(2):186–92. https://doi.org/10.1086/524668.
CAS Article PubMed Google Scholar
Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Vaccine. 2015;33(33):4146–54. https://doi.org/10.1016/j.vaccine.2015.05.081.
Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–9. https://doi.org/10.1038/s41586-021-03275-y.
CAS Article PubMed Google Scholar
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. https://doi.org/10.1038/s41586-020-2012-7.
CAS Article PubMed PubMed Central Google Scholar
Filia A, Rota MR, D’Ancona FP. Comirnaty (BNT162b2), Il primo vaccino contro il COVID-19 approvato in Europa e in Italia: Istituto Superiore di Sanità -Dipartimentomalattieinfettive; 2021. https://www.epicentro.iss.it/vaccini/covid-19-vaccino-pfizer-biontech
Cavalcanti E, Isgrò MA, Rea D, Di Capua L, Trillò G, Russo L, et al. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy). Infect Agent Cancer. 2021;16(1):32. https://doi.org/10.1186/s13027-021-00375-2.
CAS Article PubMed PubMed Central Google Scholar
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. https://doi.org/10.1126/science.abf4063.
CAS Article PubMed Google Scholar
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372–4. https://doi.org/10.1056/NEJMc2101667.
CAS Article PubMed Google Scholar
Padoan A, Dall’Olmo L, Rocca FD, Barbaro F, Cosma C, Basso D, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60–3. https://doi.org/10.1016/j.cca.2021.04.006.
CAS Article PubMed PubMed Central Google Scholar
Blain H, Tuaillon E, Gamon L, Pisoni A, Miot S, Picot MC, et al. Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. JAMA. 2021;325(18):1898–9. https://doi.org/10.1001/jama.2021.6042.
CAS Article PubMed Central Google Scholar
Buonaguro FM, Botti G, Ascierto PA, Pignata S, Ionna F, Delrio P, et al. The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic. Infect Agents Cancer. 2020;15:69. https://doi.org/10.1186/s13027-020-00330-7.
Zaccaro DJ, Wagener DK, Whisnant CC, Staats HF. Evaluation of vaccine-induced antibody responses: impact of new technologies. Vaccine. 2013;31(25):2756–61. https://doi.org/10.1016/j.vaccine.2013.03.065.
CAS Article PubMed PubMed Central Google Scholar
Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, et al. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. J Clin Investig. 2021;131(12): e149154. https://doi.org/10.1172/JCI149154.
CAS Article PubMed Central Google Scholar
Pang NY, Pang AS, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Military Med Res. 2021;8:47. https://doi.org/10.1186/s40779-021-00342-3.
Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, et al. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021;373(6556):eabh1766. https://doi.org/10.1126/science.abh1766.
CAS Article PubMed PubMed Central Google Scholar
Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, et al. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. NPJ Vaccines. 2021;6(1):78. https://doi.org/10.1038/s41541-021-00337-0.
CAS Article PubMed PubMed Central Google Scholar
Tretyn A, Szczepanek J, Skorupa M, Jarkiewicz-Tretyn J, Sandomierz D, Dejewska J, et al. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 recovery or post-vaccination. Cells. 2021;10(8):1952. https://doi.org/10.3390/cells10081952.
CAS Article PubMed PubMed Central Google Scholar
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. https://doi.org/10.1056/NEJMoa2114583.
CAS Article PubMed Google Scholar
Harper DM, DeMars LR. HPV vaccines—a review of the first decade. Gynecol Oncol. 2017;146(1):196–204. https://doi.org/10.1016/j.ygyno.2017.04.004.
CAS Article PubMed Google Scholar
Wen GP, He L, Tang ZM, Wang SL, Zhang X, Chen YZ, et al. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nat Commun. 2020;11:3971. https://doi.org/10.1038/s41467-020-17737-w.
CAS Article PubMed PubMed Central Google Scholar
Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, et al. Antibody response to SARS-CoV-2 for more than one year—kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol. 2022;146: 105052. https://doi.org/10.1016/j.jcv.2021.105052.
CAS Article PubMed Google Scholar
Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41(6):457–65. https://doi.org/10.1016/j.it.2020.04.001.
CAS Article PubMed PubMed Central Google Scholar
Jogalekar MP, Veerabathini A, Gangadaran P. SARS-CoV-2 variants: A double-edged sword? Exp Biol Med (Maywood). 2021;246(15):1721–6. https://doi.org/10.1177/15353702211014146.
Schiøler H, Knudsen T, Brøndum RF, Stoustrup J, Bøgsted M. Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction. Sci Rep. 2021;11(1):24498. https://doi.org/10.1038/s41598-021-04108-8.
CAS Article PubMed PubMed Central Google Scholar
Chaudhry MZ, Eschke K, Hoffmann M, Grashoff M, Abassi L, Kim Y, et al. Rapid SARS-CoV-2 adaptation to available cellular proteases. J Virol. 2022. https://doi.org/10.1128/jvi.02186-21.
Article PubMed PubMed Central Google Scholar
Gerdol M, Dishnica K, Giorgetti A. Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. Virus Res. 2022;310: 198674. https://doi.org/10.1016/j.virusres.2022.198674.
留言 (0)